CanSino Biologics Inc. (HKG:6185)
Hong Kong · Delayed Price · Currency is HKD 33.94
+1.74 (5.40%)
At close: Mar 6, 2026
CanSino Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,068 | 824.88 | 345.18 | 1,031 | 4,300 |
Other Revenue | - | 21.45 | 11.9 | 3.55 | - |
| 1,068 | 846.34 | 357.08 | 1,035 | 4,300 | |
Revenue Growth (YoY) | 26.18% | 137.01% | -65.49% | -75.94% | 17174.82% |
Cost of Revenue | - | 262.76 | 800.83 | 1,218 | 1,298 |
Gross Profit | 1,068 | 583.58 | -443.75 | -183.71 | 3,002 |
Selling, General & Admin | - | 547.75 | 639.88 | 535.48 | 327.14 |
Research & Development | - | 416.12 | 637.99 | 778.26 | 878.72 |
Other Operating Expenses | 1,044 | -7.14 | -14.16 | -7.24 | 10.18 |
Operating Expenses | 1,044 | 962.95 | 1,279 | 1,315 | 1,218 |
Operating Income | 23.91 | -379.37 | -1,723 | -1,499 | 1,784 |
Interest Expense | - | -59.98 | -64.15 | -41.34 | -20.42 |
Interest & Investment Income | - | 63.87 | 173.26 | 161.89 | 125.42 |
Currency Exchange Gain (Loss) | - | 18.47 | 20.58 | 160.64 | -33.78 |
Other Non Operating Income (Expenses) | -2.18 | -5.13 | -105.44 | -0.49 | -0.28 |
EBT Excluding Unusual Items | 21.74 | -362.14 | -1,698 | -1,218 | 1,855 |
Gain (Loss) on Sale of Investments | - | -43.13 | -14.56 | -4.06 | 71.09 |
Gain (Loss) on Sale of Assets | - | 0.77 | 0.18 | - | - |
Asset Writedown | - | -1.32 | -363.19 | -0.25 | -0.25 |
Other Unusual Items | - | 24.61 | 96.31 | 38.59 | 10.93 |
Pretax Income | 21.74 | -381.2 | -1,979 | -1,184 | 1,937 |
Income Tax Expense | -6.13 | 2.47 | -12.07 | -219.24 | 29.7 |
Earnings From Continuing Operations | 27.87 | -383.67 | -1,967 | -964.76 | 1,907 |
Minority Interest in Earnings | - | 4.79 | 484.7 | 55.33 | 7.3 |
Net Income | 27.87 | -378.88 | -1,483 | -909.43 | 1,914 |
Net Income to Common | 27.87 | -378.88 | -1,483 | -909.43 | 1,914 |
Shares Outstanding (Basic) | 253 | 248 | 247 | 247 | 247 |
Shares Outstanding (Diluted) | 253 | 248 | 247 | 247 | 247 |
Shares Change (YoY) | 2.32% | 0.38% | -0.17% | -0.08% | 7.26% |
EPS (Basic) | 0.11 | -1.53 | -6.01 | -3.68 | 7.74 |
EPS (Diluted) | 0.11 | -1.53 | -6.01 | -3.68 | 7.74 |
Free Cash Flow | - | -624.93 | -1,519 | -2,927 | 846.86 |
Free Cash Flow Per Share | - | -2.52 | -6.16 | -11.84 | 3.42 |
Dividend Per Share | - | - | - | - | 0.800 |
Gross Margin | 100.00% | 68.95% | -124.27% | -17.76% | 69.82% |
Operating Margin | 2.24% | -44.82% | -482.38% | -144.89% | 41.49% |
Profit Margin | 2.61% | -44.77% | -415.23% | -87.90% | 44.52% |
Free Cash Flow Margin | - | -73.84% | -425.31% | -282.87% | 19.70% |
EBITDA | 209.33 | -193.95 | -1,482 | -1,319 | 1,849 |
EBITDA Margin | 19.60% | -22.92% | - | -127.48% | 43.01% |
D&A For EBITDA | 185.42 | 185.42 | 240.39 | 180.13 | 65.11 |
EBIT | 23.91 | -379.37 | -1,723 | -1,499 | 1,784 |
EBIT Margin | 2.24% | -44.82% | - | -144.89% | 41.49% |
Effective Tax Rate | - | - | - | - | 1.53% |
Revenue as Reported | - | 846.34 | 357.08 | 1,035 | 4,300 |
Advertising Expenses | - | - | - | - | 9.03 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.